Supply Chain Logistics

Getting a handle on level of compliance-readiness for the Drug Supply Chain Security Act deadline—now just weeks away.

The Healthcare Distribution Alliance's latest seminar was as timely as ever, with the end of the stabilization period for DSCSA implementation drawing closer.

Webinar Date/Time: Tue, Oct 22, 2024 11:00 AM EDT

The session details how these teachings span the entire pharma supply chain.

A panel offers its perspective on bolstering the temperature monitoring and data sharing process.

A panel offers insight surrounding the industry’s carbon footprint, including ways to begin initiating positive change.

Session discusses the soft skills needed to ensure that communication strategies are being followed with distributors and other logistical partners across the value chain.

With the Nov. 27 deadline fast approaching, is the pharma supply chain ready for full data exchange?

The collaboration is centered around meeting track-and-trace requirements.

Drug shortages, including critical antibiotics, fever medications, and cancer treatments, highlight global supply chain issues and the need for improved health policies to prevent medication bottlenecks.

The manufacturing line producing the company’s branded form of nirsevimab-alip has been approved by the FDA.

The company boosts its healthcare logistics services by agreeing to purchase Frigo-Trans and its sister company BPL.

In the final part of her interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, comments on industry’s preparedness for DSCSA compliance and provides an update as to where pharma is in terms of RFID label adoption.

In the second part of her interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, discusses the best practices that compliance teams should consider as the end of the stabilization period approaches this November.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, highlights the hard-hitting points that she anticipated will be covered during her session at the 2024 HDA Traceability Seminar.

How can industry stakeholders ensure the quality and supply chain security of existing product?

The 8,000 square-foot facility—located within the wholesaler’s Le Vergne distribution center— is expected to help tackle cell and gene therapy logistical challenges.

The 3PL plans to convert all its trucks to electric by 2027.

Panel offers suggestions on how compliance teams should be considering handling SOPs, stabilization, and much more.

Session uncovers distributors’ experiences with the Waiver, Exception, or Exemption request process, and how these affect the overall supply chain.

Ryan Sevek, the supplier’s CFO, will become president.

A prediction of how this shift toward patient-centric care may look.

The unveiling of the microbial fermentation manufacturing plant is headlined by a $131 million financial commitment.

The 86,000 square-foot Køge facility will be fully functional by 2027.

In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, comments on other ways to limit ‘bad actors’ attempts to sneak counterfeit drugs into the supply chain, aside from the DSCSA.

Partnership adds supply chain efficiencies, while prioritizing patient safety.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, predicts the likelihood of stabilization period postponement.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, describes the outcome of the joint public meeting held by the Partnership for DSCSA Governance and the FDA.

The partnership creates an integrated solution that also tackles compliance challenges within the sector.

Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.